ZA916556B - Method for treating inflammation,ischemia-induced cell damage and muscular dystrophy - Google Patents

Method for treating inflammation,ischemia-induced cell damage and muscular dystrophy

Info

Publication number
ZA916556B
ZA916556B ZA916556A ZA916556A ZA916556B ZA 916556 B ZA916556 B ZA 916556B ZA 916556 A ZA916556 A ZA 916556A ZA 916556 A ZA916556 A ZA 916556A ZA 916556 B ZA916556 B ZA 916556B
Authority
ZA
South Africa
Prior art keywords
ischemia
muscular dystrophy
cell damage
induced cell
treating inflammation
Prior art date
Application number
ZA916556A
Other languages
English (en)
Inventor
James Allen Clemens
Allen Clemens James
Jill Ann Panetta
Ann Panetta Jill
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA916556B publication Critical patent/ZA916556B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA916556A 1990-08-27 1991-08-19 Method for treating inflammation,ischemia-induced cell damage and muscular dystrophy ZA916556B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/572,288 US5281623A (en) 1990-08-27 1990-08-27 Method for treating inflammation

Publications (1)

Publication Number Publication Date
ZA916556B true ZA916556B (en) 1993-04-28

Family

ID=24287162

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA916556A ZA916556B (en) 1990-08-27 1991-08-19 Method for treating inflammation,ischemia-induced cell damage and muscular dystrophy

Country Status (9)

Country Link
US (2) US5281623A (fr)
EP (2) EP0680755A1 (fr)
JP (1) JPH04230623A (fr)
KR (1) KR930003908A (fr)
AU (1) AU643062B2 (fr)
CA (1) CA2049902A1 (fr)
HU (1) HUT61662A (fr)
TW (1) TW199094B (fr)
ZA (1) ZA916556B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
DE4436127A1 (de) * 1994-09-27 1996-03-28 Deutsches Rheumaforschungszent Verwendung von aromatischen Amiden und Säuren zur Behandlung von rheumatischen Erkrankungen
US5633283A (en) * 1995-01-23 1997-05-27 Eli Lilly And Company Method for treating multiple sclerosis
JPH08198756A (ja) * 1995-01-23 1996-08-06 Minsei Kagaku Kyokai 筋ジストロフィー進行抑制剤
US6028111A (en) * 1996-03-08 2000-02-22 Oxigene, Inc. Compositions and use of benzamides and nicotinamides as anti-inflammatory agents
US8946295B2 (en) * 2002-07-25 2015-02-03 Sunny Pharmtech Inc. Histone hyperacetylating agents for promoting wound healing and preventing scar formation
US20060275370A1 (en) * 2002-07-25 2006-12-07 Yih-Lin Chung Method and compositions for treatment of epithelial damage
US8883148B2 (en) * 2002-04-26 2014-11-11 Asan Laboratories Company (Cayman), Limited Prevention of joint destruction
US6809118B2 (en) * 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
US8163764B2 (en) * 2002-04-26 2012-04-24 Asan Laboratories Company (Cayman) Limited Skincare methods
US8846039B2 (en) * 2002-04-26 2014-09-30 Asan Laboratories Company (Cayman), Limited Method for ameliorating pruritus
WO2014190250A1 (fr) * 2013-05-23 2014-11-27 The Johns Hopkins University Activateurs de guanylate cyclase soluble et leur utilisation en traitement de maladie de duchenne de boulogne et de maladie apparentée
BR112018004249A2 (pt) * 2015-09-04 2018-12-04 Shin Poong Pharmaceutical Co., Ltd. composto, e, composição para prevenção ou tratamento de doenças trombóticas.
US10449198B2 (en) 2016-07-01 2019-10-22 The University Of Liverpool Method for treating pain

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3043774A (en) * 1955-09-23 1962-07-10 Ethyl Corp Organic compositions
NL281258A (fr) * 1961-07-28 1900-01-01 United States Rubber Co
US3305483A (en) * 1964-12-03 1967-02-21 Ethyl Corp Stabilized organic compositions
US3714365A (en) * 1970-03-12 1973-01-30 Ethyl Corp Reducing abnormally high plasma lipid levels in mammals with phenols
US3809761A (en) * 1970-03-12 1974-05-07 Ethyl Corp Method for reducing plasma lipid levels
US3792170A (en) * 1972-03-14 1974-02-12 Merck & Co Inc Novel alkylsulfinyl derivatives for pain,fever and inflammation
DE2240609A1 (de) * 1972-08-18 1974-02-28 Hoechst Ag Stoffwechselwirksame derivate der 4-hydroxy-3,5-di-alkylphenyl-propionsaeure
GB1405767A (en) * 1972-12-14 1975-09-10 Ethyl Corp Method formulation and pharmaceutical composition for reducing plasma lipid levels
US3994828A (en) * 1973-06-07 1976-11-30 Dynapol Corporation Nonabsorbable antioxidant
US4116930A (en) * 1975-11-03 1978-09-26 Ciba-Geigy Corporation Pyromellitic dimiides of 3,5-dialkyl-4-hydroxyphenylsubstituted amines
JPS52125170A (en) * 1976-04-12 1977-10-20 Yoshitomi Pharmaceut Ind Ltd Pyridine derivatives
US4128664A (en) * 1977-05-16 1978-12-05 Riker Laboratories, Inc. Substituted benzamides as anti-inflammatory agents
US4324717A (en) * 1980-06-23 1982-04-13 The B. F. Goodrich Company Norbornene polymers stabilized with hindered aromatic alcohols
US4562201A (en) * 1982-07-26 1985-12-31 American Hospital Supply Corporation Aminomethyl benzanilides
GB8301754D0 (en) * 1983-01-21 1983-02-23 Fisons Plc Formulation
IT1194325B (it) * 1983-07-19 1988-09-14 Simes Composizioni farmaceutiche comprendenti epinina o un suo sale farmaceuticamente accettabile e loro uso terapeutico
JPS6061523A (ja) * 1983-09-16 1985-04-09 Shionogi & Co Ltd 経口用ドブタミン製剤
US4532356A (en) * 1983-11-16 1985-07-30 Ethyl Corporation Chemical process
JPS61106545A (ja) * 1984-10-31 1986-05-24 Yamanouchi Pharmaceut Co Ltd 4−(ω−アミノアルキル)ピロカテコ−ル
AU587217B2 (en) * 1985-01-15 1989-08-10 Glaxo Group Limited Amine derivatives
GB8501646D0 (en) * 1985-01-23 1985-02-27 Nipa Lab Ltd Control of micro-organisms
GB8603765D0 (en) * 1986-02-15 1986-03-19 Beecham Wuelfung Gmbh & Co Kg Compounds
US5036157A (en) * 1986-03-11 1991-07-30 Burroughs Wellcome Co. Aryl derivatives
US4959503A (en) * 1986-04-11 1990-09-25 Warner-Lambert Company Diarylalkanoids having activity as lipoxygenase inhibitors
US4708966A (en) * 1986-06-27 1987-11-24 The Procter & Gamble Company Novel anti-inflammatory agents, pharmaceutical compositions and methods for reducing inflammation
IT1204416B (it) * 1986-06-27 1989-03-01 Midy Spa Medicamenti a base di analoghi di feniletanolammine per il trattamento di disturbi gastro-intestinali ed uterini
US4861798A (en) * 1986-12-29 1989-08-29 Bristol-Myers Company Lipoxygenase inhibitory compounds
US5171882A (en) * 1987-01-12 1992-12-15 Eli Lilly And Company Leukotriene antagonists
JPS63185923A (ja) * 1987-01-28 1988-08-01 Otsuka Pharmaceut Factory Inc 抗炎症剤
DE3702755A1 (de) * 1987-01-30 1988-08-11 Hoechst Ag 3,5-di-tert.-butyl-4-hydroxybenzoesaeureamid, verschiedene von dessen derivaten, verfahren zur herstellung dieser verbindungen, die sie enthaltenden arzneimittel und ihre verwendung
PT86919B (pt) * 1987-03-10 1992-05-29 Beecham Group Plc Metodo para a utilizacao de derivados de morfolina em medicina e agricultura e respectivo processo de preparacao
ATE149089T1 (de) * 1987-09-15 1997-03-15 Rowett Research Inst Anwendungsgebiete von beta-adrenergenen agonisten
US4948813A (en) * 1987-11-30 1990-08-14 E. I. Du Pont De Nemours And Company Benzylketone phospholipase A2 inhibitors
US5108363A (en) * 1988-02-19 1992-04-28 Gensia Pharmaceuticals, Inc. Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist
US5039805A (en) * 1988-12-08 1991-08-13 Hoffmann-La Roche Inc. Novel benzoic and phenylacetic acid derivatives
DE3903989A1 (de) * 1989-02-10 1990-09-20 Basf Ag Diphenylheteroalkylderivate, ihre herstellung und daraus hergestellte arzneimittel und kosmetika
EP0385043A1 (fr) * 1989-02-28 1990-09-05 Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. (Faes) Dérivés de pipérazinessubstituées en 4

Also Published As

Publication number Publication date
KR930003908A (ko) 1993-03-22
TW199094B (fr) 1993-02-01
HU912793D0 (en) 1992-01-28
US5281623A (en) 1994-01-25
US5393786A (en) 1995-02-28
JPH04230623A (ja) 1992-08-19
AU8278391A (en) 1992-03-05
CA2049902A1 (fr) 1992-02-28
EP0680755A1 (fr) 1995-11-08
EP0476846A2 (fr) 1992-03-25
EP0476846A3 (en) 1992-08-05
HUT61662A (en) 1993-03-01
AU643062B2 (en) 1993-11-04

Similar Documents

Publication Publication Date Title
GB2278236B (en) Photovoltaic cell and method
GB2224954B (en) Cell processing apparatus and method
GB9207861D0 (en) A method of time measurement in a communications system,a communications system and a receiving apparatus for use in the system
AU687122B2 (en) Apparatus and method for step-charging batteries to optimize charge acceptance
GB9409443D0 (en) Method and apparatus for estimating battery capacity
GB9325120D0 (en) Energy transfer divece and method
IL115867A0 (en) Organic fuel cell methods and apparatus
PH31128A (en) Apparatus and method for securing building during high wind conditions.
EP0493962A3 (en) Method and apparatus for improving bit-images
EP0691038A4 (fr) Procede et appareil utilises pour recharger des accumulateurs
ZA916556B (en) Method for treating inflammation,ischemia-induced cell damage and muscular dystrophy
AU6930191A (en) Figure drawing method and apparatus
EP0666602A3 (fr) Cellule solaire et procédé de fabrication.
GB9115457D0 (en) Centreless runout and profile system and method
EP0542233A3 (en) Cell switching apparatus and method
HUT58898A (en) Method and apparatus for drying wood-veneer plates and similars
HK89097A (en) Arrangement and method for detecting interference in TDMA communications system
GB2216337B (en) Solar cell and fabrication method thereof
EP0660422A3 (fr) Méthode et dispositif pour la fabrication de cellules photovoltaiques.
GB9126836D0 (en) Method and apparatus for processing used batteries
GB2239788B (en) Method and apparatus for washing storage batteries
GB2295510B (en) Apparatus and method for maintaining the charge of a battery
GB9019970D0 (en) Fence,extension for use in a fence and method of extending a fence
NZ236320A (en) Packet handling method in communications system
AU4589093A (en) Metering apparatus, and metering method